Trials / Recruiting
RecruitingNCT07283315
Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paediatric B Cell-related Autoimmune Diseases
Exploratory Clinical Study on the Safety and Efficacy of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paediatric B Cell-related Autoimmune Diseases
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine · Academic / Other
- Sex
- All
- Age
- 3 Years
- Healthy volunteers
- Not accepted
Summary
Evaluating the efficacy and safety of anti-CD19/BCMA CAR-NK Cells in Paediatric B cell-related autoimmune diseases
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | anti-CD19/BCMA CAR NK cells (KN5601-K) | The study adopted a dose-escalation and expansion study design. All subjects will receive fludarabine/ cyclophosphamide lymphodepletion followed by anti-CD19/BCMA CAR NK cells infusion. |
Timeline
- Start date
- 2025-12-03
- Primary completion
- 2028-12-30
- Completion
- 2029-12-30
- First posted
- 2025-12-15
- Last updated
- 2026-02-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07283315. Inclusion in this directory is not an endorsement.